An update on male hypogonadism therapy.
An update on male hypogonadism therapy.
复制标题
DOI：
10.1517/14656566.2014.913022
复制
发表时间：
2014-06
影响因子：
3.2
通讯作者：
Wang C
中科院分区：
文献类型：
--
作者：
Surampudi P;Swerdloff RS;Wang C
有持续低血清总睾酮水平相关症状的男性应评估睾酮替代治疗。急性和慢性疾病与低血清睾酮有关，这些都应该得到承认和治疗。一旦诊断为男性性腺功能减退症，睾酮治疗的好处通常超过风险。如果没有禁忌症，患者应提供睾酮替代治疗。在过去的十年中，睾酮递送系统（注射剂、透皮贴剂/凝胶、口含片、胶囊和植入物）的选择有所增加。替吉奥改善性腺功能减退症的症状和体征，如性功能和能量，增加骨密度和瘦体重，减少内脏肥胖。对于希望生育的男性和继发性性腺功能减退的男性，可以停用睾酮，并给予促性腺激素。新的改良设计雄激素和选择性雄激素受体调节剂已在临床前和临床试验一段时间。这些药物均未被评估用于治疗男性性腺功能减退症。尽管缺乏前瞻性的长期数据，随机对照临床试验的睾酮治疗前列腺健康和心血管疾病的风险，现有的证据表明，睾酮治疗应提供给症状性性腺功能减退的男性。
Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.
登录
查看更多内容
2001 年至 2011 年美国雄激素处方趋势。
影响因子：
39
作者：
Baillargeon, Jacques;Urban, Randall J.;Ottenbacher, Kenneth J.;Pierson, Karen S.;Goodwin, James S.
通讯作者：
Goodwin, James S.
DOI：
10.1056/nejmoa1000485
发表时间：
2010-07-08
期刊：
The New England journal of medicine
影响因子：
--
作者：
Basaria S;Coviello AD;Travison TG;Storer TW;Farwell WR;Jette AM;Eder R;Tennstedt S;Ulloor J;Zhang A;Choong K;Lakshman KM;Mazer NA;Miciek R;Krasnoff J;Elmi A;Knapp PE;Brooks B;Appleman E;Aggarwal S;Bhasin G;Hede-Brierley L;Bhatia A;Collins L;LeBrasseur N;Fiore LD;Bhasin S
通讯作者：
Bhasin S
影响因子：
3.5
作者：
Aversa, Antonio;Bruzziches, Roberto;Spera, Giovanni
通讯作者：
Spera, Giovanni
影响因子：
4.8
作者：
Attardi, Barbara J.;Hild, Sheri A.;Reel, Jerry R.
通讯作者：
Reel, Jerry R.
影响因子：
3.2
作者：
Atlantis, Evan;Martin, Sean A.;Wittert, Gary A.
通讯作者：
Wittert, Gary A.